Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults

Vaccine

Volumn 31, Issue 2, 2013, Pages 327-333

  Kamtchoua, Thierry ^a   Bologa, Monica ^b   Hopfer, Robert ^c   Neveu, David ^c   Hu, Branda ^c   Sheng, Xiaohua ^c   Corde, Nicolas ^c   Pouzet, Catherine ^c   Zimmermann, Gloria ^a   Gurunathan, Sanjay ^c  

^a Covance Clinical Research Unit AG ^*  (Switzerland)

^b Sanofi Pasteur   (Canada)

^c SANOFI PASTEUR   (France)

Author keywords

Clinical trial; Detoxified pneumolysin; Immunogenicity; Protein vaccine; Safety; Toxin neutralization

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G; PLACEBO; PNEUMOCOCCAL PNEUMOLYSIN DERIVATIVE VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWELLING;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUMINUM HYDROXIDE; ANTIBODY FORMATION; BACTERIAL PROTEINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PILOT PROJECTS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; YOUNG ADULT;

EID: 84871361255     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.005     Document Type: Article

References (41)

1. Weinberger D.M., Dagan R., Givon-Lavi N., Regev-Yochay G., Malley R., Lipsitch M. Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J Infect Dis 2008, 197(June (11)):1511-1518.
2. World Health Organization Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007, 82(March (12)):93-104.
3. Black S., Eskola J., Whitney C., Shienfeld H. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. Vaccines 2008, 531-567. Saunders Elsevier, Amsterdam. S. Plotkin, W. Orenstein, P. Offit (Eds.).
4. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009, 30(April (2)):189-209.
5. Rozenbaum M.H., Boersma C., Postma M.J., Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2011, 10(February (2)):187-199.
6. Dominguez A., Ciruela P., Garcia-Garcia J.J., Moraga F., de Sevilla M.F., Selva L., et al. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. Vaccine 2011, 29(November (48)):9020-9025.
7. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29(November (49)):9127-9131.
8. Mera R., Miller L.A., Fritsche T.R., Jones R.N. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 2008, 14(June (2)):101-107.
9. McIntosh E.D., Reinert R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011, 10(January (1)):109-129.
10. Paton J., Boslego J. Protein vaccines. Pneumococcal vaccines: the impact of conjugate vaccine 2008, 421-436. ASM Press, Washington, DC. G. Siber, K. Klugman, P. Makela (Eds.).
11. Marriott H.M., Mitchell T.J., Dockrell D.H. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med 2008, 8(September (6)):497-509.
12. Rubins J.B., Charboneau D., Fasching C., Berry A.M., Paton J.C., Alexander J.E., et al. Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia. Am J Respir Crit Care Med 1996, 153(April (4 Pt 1)):1339-1346.
13. Jounblat R., Kadioglu A., Mitchell T.J., Andrew P.W. Pneumococcal behavior and host responses during bronchopneumonia are affected differently by the cytolytic and complement-activating activities of pneumolysin. Infect Immun 2003, 71(April (4)):1813-1819.
14. Calbo E., Garau J. Factors affecting the development of systemic inflammatory response syndrome in pneumococcal infections. Curr Opin Infect Dis 2011, 24(June (3)):241-247.
15. Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipsitch M., Thompson C.M., et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003, 100(February (4)):1966-1971.
16. Musher D.M., Phan H.M., Baughn R.E. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis 2001, 183(March (5)):827-830.
17. Zhang Q., Bagrade L., Bernatoniene J., Clarke E., Paton J.C., Mitchell T.J., et al. Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children. J Infect Dis 2007, 195(April (8)):1194-1202.
18. Witzenrath M., Gutbier B., Hocke A.C., Schmeck B., Hippenstiel S., Berger K., et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 2006, 34(July (7)):1947-1954.
19. Feldman C., Munro N.C., Jeffery P.K., Mitchell T.J., Andrew P.W., Boulnois G.J., et al. Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo. Am J Respir Cell Mol Biol 1991, 5(November (5)):416-423.
20. Kaur R., Casey J.R., Pichichero M.E. Serum antibody response to five Streptococcus pneumoniae proteins during acute otitis media in otitis-prone and non-otitis-prone children. Pediatr Infect Dis J 2011, 30(August (8)):645-650.
21. Mitchell T.J., Mendez F., Paton J.C., Andrew P.W., Boulnois G.J. Comparison of pneumolysin genes and proteins from Streptococcus pneumoniae types 1 and 2. Nucleic Acids Res 1990, 18(July (13)):4010.
22. Alexander J.E., Lock R.A., Peeters C.C., Poolman J.T., Andrew P.W., Mitchell T.J., et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994, 62(December (12)):5683-5688.
23. Ljutic B., Ochs M., Messham B., Ming M., Dookie A., Harper K., et al. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Vaccine 2012, 30(April (19)):2981-2988.
24. Oloo E.O., Yethon J.A., Ochs M.M., Carpick B., Oomen R. Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease. J Biol Chem 2011, 286(April (14)):12133-12140.
25. Miyamura K., Tajiri E., Ito A., Murata R., Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. II. Comparison with the rabbit skin method and practical application for seroepidemiological studies. J Biol Stand 1974, 2(July (3)):203-209.
26. Collett D. Modelling binary data 2002, Chapman, Hall/CRC, Boca Raton, FL. 2nd ed.
27. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998, 17(April (8)):857-872.
28. Zou K.H., Tuncali K., Silverman S.G. Correlation and simple linear regression. Radiology 2003, 227(June (3)):617-622.
29. Balloch A., Licciardi P.V., Leach A., Nurkka A., Tang M.L. Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance. Vaccine 2010, 28(February (5)):1333-1340.
30. Licciardi P.V., Balloch A., Russell F.M., Burton R.L., Lin J., Nahm M.H., et al. Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol 2012, 129(March (3)). 794-800 e2.
31. Holmlund E., Nohynek H., Quiambao B., Ollgren J., Kayhty H. Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination. Vaccine 2011, 29(June (28)):4565-4575.
32. Ogunniyi A.D., Woodrow M.C., Poolman J.T., Paton J.C. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 2001, 69(October (10)):5997-6003.
33. Briles D.E., Hollingshead S.K., Paton J.C., Ades E.W., Novak L., van Ginkel F.W., et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 2003, 188(August (3)):339-348.
34. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82(October (5)):497-505.
35. Lode H., Schmoele-Thoma B., Gruber W., Ahlers N., Fernsten P., Baker S., et al. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older. Vaccine 2011, 29(July (31)):4940-4946.
36. Jefferies J.M., Johnston C.H., Kirkham L.A., Cowan G.J., Ross K.S., Smith A., et al. Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks. J Infect Dis 2007, 196(September (6)):936-944.
37. Salha D., Szeto J., Myers L., Claus C., Sheung A., Tang M., et al. Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun 2012, 80(June (6)):2212-2220.
38. Holmlund E., Quiambao B., Ollgren J., Jaakkola T., Neyt C., Poolman J., et al. Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage. Clin Vaccine Immunol 2009, 16(June (6)):916-923.
39. Holmlund E., Quiambao B., Ollgren J., Nohynek H., Kayhty H. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 2006, 24(January (1)):57-65.
40. Rapola S., Jantti V., Haikala R., Syrjanen R., Carlone G.M., Sampson J.S., et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 2000, 182(October (4)):1146-1152.
41. Zhang Q., Bernatoniene J., Bagrade L., Pollard A.J., Mitchell T.J., Paton J.C., et al. Serum and mucosal antibody responses to pneumococcal protein antigens in children: relationships with carriage status. Eur J Immunol 2006, 36(January (1)):46-57.